|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-6-28
|
|
pubmed:abstractText |
Antimonials are the mainstay of visceral leishmaniasis (VL) treatment in Africa. The increasing incidence of human immunodeficiency virus (HIV) coinfection requires alternative safe and effective drug regimens. Oral miltefosine has been proven to be safe and effective in the treatment of Indian VL but has not been studied in Africa or in persons with HIV and VL coinfection.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
43
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
357-64
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16804852-Adult,
pubmed-meshheading:16804852-Antimony Sodium Gluconate,
pubmed-meshheading:16804852-Antiprotozoal Agents,
pubmed-meshheading:16804852-Comorbidity,
pubmed-meshheading:16804852-Ethiopia,
pubmed-meshheading:16804852-HIV Infections,
pubmed-meshheading:16804852-Humans,
pubmed-meshheading:16804852-Leishmaniasis, Visceral,
pubmed-meshheading:16804852-Male,
pubmed-meshheading:16804852-Phosphorylcholine,
pubmed-meshheading:16804852-Prevalence,
pubmed-meshheading:16804852-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
|
|
pubmed:affiliation |
Médecins Sans Frontières-Holland, Amsterdam, The Netherlands. koert.ritmeijer@amsterdam.msf.org
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial
|
